Medigene participates at four national and international conferences in January 2017
(Thomson Reuters ONE) -
Medigene AG /
Medigene participates at four national and international conferences in January
2017
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 16 December 2016. Medigene AG (FSE: MDG1, Prime Standard)
announces its participation at four upcoming scientific and investor
conferences:
* Ringberg Conference 2017
Date: 03 January 2017
Location: Schloss Ringberg, Tegernsee, Germany
Dr. Markus Dangl, Senior Vice President Research & Pre-Clinical
Development, will give a presentation on the topic: "TCRs and neoantigens: The
perfect solution for personalized cancer immunotherapy?"
* Oddo Forum
Date: 05 - 06 January 2017
Location: Lyon, France
* J.P. Morgan Healthcare Conference
Date: 09 - 12 January 2017
Location: San Francisco, USA
* Phacilitate, Cell & Gene World 2017
Date: 17 - 20 January 2017
Location: Miami, USA
Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai
Pinkernell, will present on 18 January 2017 a case study in the session:
"Optimizing preclinical data packages for efficient cell & gene therapy clinical
translation"
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed
biotechnology company headquartered in Martinsried near Munich, Germany. The
company is developing highly innovative, complementary treatment platforms to
target various types and stages of cancer with candidates in clinical and pre-
clinical development. Medigene concentrates on the development of personalized T
cell-based immunotherapies.
For more information, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(® )is a registered trademark of Medigene AG. This trademark may be
owned or licensed in select locations only.
Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor(at)medigene.com
In case you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor(at)medigene.com). We will then delete your address
from our distribution list.
Press release English PDF:
http://hugin.info/132073/R/2065767/775453.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 16.12.2016 - 07:30 Uhr
Sprache: Deutsch
News-ID 513340
Anzahl Zeichen: 3266
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 319 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene participates at four national and international conferences in January 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
